Ann Hamilton is a Professor in the Department of Preventive Medicine in the Keck School of Medicine at the University of Southern California (USC) and the SEER Data Collection Core Co-Director. She received her Ph. D. from UCLA’s School of Public Health. Dr. Hamilton has a background in cancer epidemiology and her research has focused on etiology of breast and germ cell cancers. She has also studied cancer outcomes related to breast, prostate, NHL and other cancers. Dr. Hamilton has been the P.I. of several cancer registry-based NCI-SEER funded studies to assess quality of care received by cancer patients, as well as quality of life, late and long term effects of cancer, information needs, and how decisions are made regarding treatment. Recently she has been studying health behaviors and long term survivorship concerns among childhood cancer survivors. Dr. Hamilton also assists other researchers who wish to utilize the Cancer Surveillance Program, the SEER registry for Los Angeles County which is located at USC. As part of the CanSORT P01, Dr. Hamilton leads USC site operations for the Survey Development and Data Collection Core.

Selected Publications

Hamilton AS, Fleming ST, Wang D, Goodman M, Wu XC, Owen JB, Lo M, Ho A, Anderson RT, Thompson T. Clinical and Demographic Factors Associated With Receipt of Non Guideline-concordant Initial Therapy for Nonmetastatic Prostate Cancer. Am J Clin Oncol 2014 [Epub]

Hamilton AS, Wu XC, Lipscomb J, Fleming ST, Lo M, Wang D, Goodman M, Ho A, Owen JB, Rao C, German RR.Regional, provider, and economic factors associated with the choice of active surveillance in the treatment of men with localized prostate cancer. J Natl Cancer Inst Monogr 2012; (45):213-20

Hamilton, A.S. Quality of life research: adding an important dimension to the evaluation of therapeutic outcomes. Leuk Lymphoma 2011; 5293):353-4

Hamilton AS, Hofer TP, Hawley ST, Morrell D, Leventhal M, Deapen D, Salem B, Katz SJ. Latinas and Breast Cancer Outcomes: Population-based sampling, Ethnic Identity and Acculturation Assessment. Cancer Epidemiol Biomarkers Prev 2009; 18(7):2022-2029